HK inno.N Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HK inno.N Corp.
Korea Q4 Roundup: International Growth A Key Factor For Major Firms
Aside from record earnings reported by a number of Korean pharma companies, the industry saw a diverse range of headlines in the fourth quarter, including cross-border acquisitions and business diversification.
KoNECT Talkshow: What Defines Success In New Drug Development?
At a recent conference in Seoul, senior executives shared views on a broad array of topics around developing globally successful new drugs in an extremely competitive environment, including what could be considered as success. Awareness of patient needs and social value emerged as some key threads.
The Race Is On. When Will Korea Have Its Own Approved Gene Therapy?
Scrip takes a look at the landscape of the South Korean gene and cell therapy sector, which is under the spotlight with the implementation of a new cutting-edge biologics law.
Asia Deal Watch: Innovent And Bolt Collaborate On Immune-Stimulating Antibody Conjugates
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
- Contract Manufacturing Organization
- Drug Delivery
- OTC, Consumer
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- CJ HealthCare Corp.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.